Market capitalization | $306.38m |
Enterprise Value | $197.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.37 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-81.50m |
Free Cash Flow (TTM) Free Cash Flow | $-61.02m |
Cash position | $140.61m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
5 Analysts have issued a Nautilus Biotechnology forecast:
5 Analysts have issued a Nautilus Biotechnology forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -6.39 -6.39 |
27%
27%
|
|
EBITDA | -75 -75 |
11%
11%
|
EBIT (Operating Income) EBIT | -81 -81 |
12%
12%
|
Net Profit | -70 -70 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nautilus Biotechnology, Inc. develops proteomics platform for analyzing and quantifying the human proteome. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Sujal Patel |
Employees | 167 |
Founded | 2016 |
Website | www.nautilus.bio |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.